Back to Search
Start Over
Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability.
- Source :
-
JAMA [JAMA] 2022 May 03; Vol. 327 (17), pp. 1647-1648. - Publication Year :
- 2022
- Subjects :
- Costs and Cost Analysis
United States
Drug Costs legislation & jurisprudence
Drug Industry economics
Drug Industry legislation & jurisprudence
Health Services Accessibility economics
Health Services Accessibility legislation & jurisprudence
Medicaid economics
Medicaid legislation & jurisprudence
Subjects
Details
- Language :
- English
- ISSN :
- 1538-3598
- Volume :
- 327
- Issue :
- 17
- Database :
- MEDLINE
- Journal :
- JAMA
- Publication Type :
- Academic Journal
- Accession number :
- 35426909
- Full Text :
- https://doi.org/10.1001/jama.2022.5959